Skip to content

Immuno-Oncology Models

Conventional tumor models with immunodeficient animals only monitor the effect of a drug on the tumor itself. The approval in 2011 of the first immune-checkpoint inhibitor (Nobel Prize Winner in 2018) has validated the immuno-oncology therapeutic approach against many forms of cancer.

TransCure bioServices has developed one of the most predictive preclinical immuno-oncology mouse models. Engraftment of tumor cells lines (CDX) or patient-derived xenografts (PDX) in our CD34+ humanized mouse models fully recapitulate the cancer disease.

Thanks to our strong expertise in CD34+ humanized mouse models, TransCure BioServices can provide custom study designs in order to: analyze PK/PD response of your drug candidates, assess the therapeutic efficacies, and/or decipher their mechanisms of action.

Preclinical IO study

Preclinical IO study

We have a list of fully characterized tumor cell lines and can provide access to their tumor micro-environment (TME) infiltration data, so you can choose the best tumor model for your specific needs.

Tumor Immuno-phenotype

Tumor Immuno-phenotype

Drug testing in our humanized mouse models will allow you test mechanisms of actions such as: Immune-checkpoint inhibitors (ICP), ADCC, Phagocytosis, T-cell engagers, NK-bispecifics, cytokines, cell therapies, and CAR-based therapies.

Immune-checkpoint inhibitor and T cells exhaustion

Immune-checkpoint inhibitor and T cells exhaustion

CAR-T cells and hu-mouse models

CAR-T cells and hu-mouse models

Read-outs:

Other mouse models are also available: